Search hospitals > Missouri > Liberty
BVL Clinical Research
Claim this profileLiberty, Missouri 64068
Conducts research for Ulcerative Colitis
Conducts research for Crohn's Disease
Conducts research for Inflammatory Bowel Disease
Conducts research for Ulcer
5 reported clinical trials
1 medical researcher
Summary
BVL Clinical Research is a medical facility located in Liberty, Missouri. This center is recognized for care of Ulcerative Colitis, Crohn's Disease, Inflammatory Bowel Disease, Ulcer and other specialties. BVL Clinical Research is involved with conducting 5 clinical trials across 4 conditions. There are 1 research doctors associated with this hospital, such as Christopher Bartalos, MD.Top PIs
Clinical Trials running at BVL Clinical Research
Ulcerative Colitis
Crohn's Disease
Inflammatory Bowel Disease
Ulcer
Vedolizumab + Tofacitinib
for Ulcerative Colitis
The main aim of this study is to learn about the effect of treatment with vedolizumab IV (vedolizumab) together with tofacitinib in adults with moderate and severe ulcerative colitis (UC). Another aim is to learn about treatment with Vedolizumab alone after the double treatment. All participants will receive vedolizumab together with tofacitinib for 8 weeks and will be checked for response. Participants who show a response to the treatment after 8 weeks will be treated with vedolizumab alone for an additional 44 weeks. Each participant will be followed up for at least 26 weeks after the last dose of vedolizumab.
Recruiting3 awards Phase 47 criteria
ABX464 Maintenance Therapy
for Ulcerative Colitis
This is a multicenter, randomized study to evaluate the long-term efficacy and safety of ABX464 50mg and 25mg administered once daily (QD) as maintenance therapy in subjects with moderately to severely active ulcerative colitis who have inadequate response, no response, a loss of response, or an intolerance to either conventional therapies [corticosteroids, immunosuppressant (i.e. azathioprine, 6-mercaptopurine, methotrexate)] and/or advanced therapies [biologics (TNF inhibitors, anti-integrins, anti-IL-23), and/or S1P receptor modulators, and/or JAK inhibitors]. This study is the maintenance phase of both previous induction studies ABX464-105 and ABX464-106. All eligible subjects who have completed either one of the induction studies above mentioned, will be given the opportunity to take part in the present ABX464-107 maintenance study and will be randomized to either a double blind, placebo-controlled part (Part #1) or allocated to ABX464 50mg or 25mg open label treatment arms (Part #2) depending on their clinical response at the end of induction. This study consists of a 44-week treatment phase and a 28-days follow-up period consisting in the End of Study (EOS) visit.
Recruiting1 award Phase 3
ABX464
for Ulcerative Colitis
This is a multicenter, randomized, placebo controlled study to evaluate the efficacy and safety of ABX464 given at 25 or 50 mg QD in inducing clinical remission in subjects with moderately to severely active ulcerative colitis who have inadequate response, no response, a loss of response, or an intolerance to either conventional therapies [corticosteroids, immunosuppressant (i.e. azathioprine, 6-mercaptopurine, methotrexate)] and/or advanced therapies [biologics (TNF inhibitors, anti-integrins, anti-IL-23), and/or S1P receptor modulators, and/or JAK inhibitors].
Recruiting1 award Phase 36 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at BVL Clinical Research?
BVL Clinical Research is a medical facility located in Liberty, Missouri. This center is recognized for care of Ulcerative Colitis, Crohn's Disease, Inflammatory Bowel Disease, Ulcer and other specialties. BVL Clinical Research is involved with conducting 5 clinical trials across 4 conditions. There are 1 research doctors associated with this hospital, such as Christopher Bartalos, MD.